PET

Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis

Retrieved on: 
Monday, June 5, 2023

Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory diseases including multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).
  • A reduction in microglial activation is associated with lowered inflammation in the brain.
  • Inflammation in the brain drives the disease pathology in multiple sclerosis.
  • This finding is even more remarkable because all of the 6 expanded access patients’ na-SPMS had clinically regressed on ocrelizumab treatment.

Sprouts Farmers Market Releases Environmental, Social and Governance (ESG) Report for 2022

Retrieved on: 
Monday, June 5, 2023

The company’s work focuses on offering sustainably and responsibly sourced products, eliminating waste and fighting hunger, reducing its carbon footprint, and plastics reduction.

Key Points: 
  • The company’s work focuses on offering sustainably and responsibly sourced products, eliminating waste and fighting hunger, reducing its carbon footprint, and plastics reduction.
  • “I’m proud to share the strong progress we made in our ESG initiatives over the past year.
  • Highlights from the 2022 report include:
    Completed scope 3 carbon emissions inventory.
  • Organizations supported by the Foundation provided 12 million hours of nutrition education programing to over 3 million students.

MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer

Retrieved on: 
Friday, June 2, 2023

This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer.

Key Points: 
  • This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer.
  • MEDSIR PHERGain trial is the first to use an adaptive design in HER2-positive early breast cancer.
  • PHERGain is a randomized, controlled phase 2 clinical trial that involved 356 early-stage HER2-positive breast cancer patients from 45 centers in seven European countries.
  • Among this latter group, 98.9% remained cancer-free after three years of follow-up from breast cancer surgery.

Arçelik recycles 192 million waste PET bottles, celebrating World Environment Day

Retrieved on: 
Friday, June 2, 2023

The company has successfully recycled 192 million plastic bottles from ending up in landfill from 2017 to 2022.

Key Points: 
  • The company has successfully recycled 192 million plastic bottles from ending up in landfill from 2017 to 2022.
  • These recycled materials have been incorporated into the plastic components of ovens, dishwashers, and washing machines, further reducing plastic waste.
  • From 2014 to 2022, Arçelik has demonstrated its commitment to sustainability by recycling 1.7 million Waste Electrical and Electronic Equipment (WEEE) units in leading-edge recycling plants.
  • Plastic pollution is this year's World Environment Day theme, and an issue that we take very seriously.

Arçelik recycles 192 million waste PET bottles, celebrating World Environment Day

Retrieved on: 
Friday, June 2, 2023

The company has successfully recycled 192 million plastic bottles from ending up in landfill from 2017 to 2022.

Key Points: 
  • The company has successfully recycled 192 million plastic bottles from ending up in landfill from 2017 to 2022.
  • These recycled materials have been incorporated into the plastic components of ovens, dishwashers, and washing machines, further reducing plastic waste.
  • From 2014 to 2022, Arçelik has demonstrated its commitment to sustainability by recycling 1.7 million Waste Electrical and Electronic Equipment (WEEE) units in leading-edge recycling plants.
  • Plastic pollution is this year's World Environment Day theme, and an issue that we take very seriously.

EQS-News: Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France

Retrieved on: 
Friday, June 2, 2023

Subject to the successful performance of this first plant in France, Indorama Ventures confirms its intention to potentially expand the technology to other PET sites for future developments.

Key Points: 
  • Subject to the successful performance of this first plant in France, Indorama Ventures confirms its intention to potentially expand the technology to other PET sites for future developments.
  • Pursuant to this MOU, Indorama Ventures shall ensure 100% of output repolymerization and both partners shall collaborate to secure feedstock supply.
  • Part of Carbios’ equity injection into the Joint Venture shall be financed by a portion of Carbios’ current cash position (i.e.
  • The project is part of Indorama Ventures’ Vision 2030 ambition to build on its leadership as a global sustainable chemical company.

Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France

Retrieved on: 
Thursday, June 1, 2023

Subject to the successful performance of this first plant in France, Indorama Ventures confirms its intention to potentially expand the technology to other PET sites for future developments.

Key Points: 
  • Subject to the successful performance of this first plant in France, Indorama Ventures confirms its intention to potentially expand the technology to other PET sites for future developments.
  • Pursuant to this MOU, Indorama Ventures shall ensure 100% of output repolymerization and both partners shall collaborate to secure feedstock supply.
  • The project is part of Indorama Ventures’ Vision 2030 ambition to build on its leadership as a global sustainable chemical company.
  • After successful ongoing operations in its demonstration plant in Clermont-Ferrand in France, Carbios has been collaborating with Indorama Ventures for over a year to assess the commercial and technical feasibility of the technology.

Study Confirms DISCERN™ Alzheimer’s Disease Diagnostic Projected to Save Nearly $5 Million Over Three Years for Medicare Advantage Plans, Avoids Inappropriate Prescribing of New, Expensive Medications

Retrieved on: 
Thursday, June 1, 2023

Results from the study show the DISCERN test, the only autopsy-validated skin test to detect AD, even in people recently diagnosed with dementia, can save nearly $5 million in just three years for a Medicare Advantage plan with one million beneficiaries.

Key Points: 
  • Results from the study show the DISCERN test, the only autopsy-validated skin test to detect AD, even in people recently diagnosed with dementia, can save nearly $5 million in just three years for a Medicare Advantage plan with one million beneficiaries.
  • “Ensuring patients receive accurate diagnoses is of growing urgency as upcoming AD drugs elicit safety concerns and rising costs for the US.
  • Considering the newly available anti-amyloid drugs, improving diagnostic accuracy in the community setting will likely increase the cost savings to the plans.
  • This becomes even more problematic when evaluating treatment options for patients in the early stages of dementia or mild cognitive impairment (MCI).

CAMH study confirms ongoing brain inflammation associated with long COVID

Retrieved on: 
Thursday, June 1, 2023

TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.

Key Points: 
  • TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.
  • "We already knew that there is brain inflammation in people who died in the midst of a severe, active COVID-19 infection.
  • "Inflammation in the brain was suspected of being the critical step in causing neurological and psychiatric symptoms of long COVID so confirming this is vital to develop treatments for people experiencing symptoms."
  • Most participants also experienced a variety of other lingering symptoms associated with long COVID, including extreme fatigue and problems with concentration and memory often referred to as 'brain fog'.

EQS-News: Carbios will receive grants totaling €54 million from French State via France 2030 and Grand-Est Region

Retrieved on: 
Thursday, June 1, 2023

Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).

Key Points: 
  • Carbios selected for €30 million in funding from the French State via France 2030 and €12.5 million from the Grand-Est Region, subject to ratification by the European Commission, for the construction of Carbios' first industrial plant in Longlaville (54).
  • The reference plant in Longlaville in the Grand-Est region will be the world’s first PET biorecycling plant and is due for commissioning in 2025.
  • This funding will enable to continue its research into the optimization and continuous improvement of Carbios’ enzymatic technologies.
  • They have spared no effort, with the constant support of the French State and ADEME, to make this plant a reality.